The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic Angina<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Abstract
CONTEXT: Many patients with chronic angina experience anginal episodes despite revascularization and antianginal medications. In a previous trial, antianginal monotherapy with ranolazine, a drug believed to partially inhibit fatty acid oxidation, increased treadmill exercise performance; however, its long-term efficacy and safety have not been studied in combination with beta-blockers or calcium antagonists in a large patient population with severe chronic angina. OBJECTIVES: To determine whether, at trough levels, ranolazine improves the total exercise time of patients who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem and to determine times to angina onset and to electrocardiographic evidence of myocardial ischemia, effect on angina attacks and nitroglycerin use, and effect on long-term survival in an open-label observational study extension. DESIGN, SETTING, AND PATIENTS: A randomized, 3-group parallel, double-blind, placebo-controlled trial of 823 eligible adults with symptomatic chronic angina who were randomly assigned to receive placebo or 1 of 2 doses of ranolazine. Patients treated at the 118 participating ambulatory outpatient settings in several countries were enrolled in the Combination Assessment of Ranolazine In Stable Angina (CARISA) trial from July 1999 to August 2001 and followed up through October 31, 2002. INTERVENTION: Patients received twice-daily placebo or 750 mg or 1000 mg of ranolazine. Treadmill exercise 12 hours (trough) and 4 hours (peak) after dosing was assessed after 2, 6 (trough only), and 12 weeks of treatment. MAIN OUTCOME MEASURES: Change in exercise duration, time to onset of angina, time to onset of ischemia, nitroglycerin use, and number of angina attacks. RESULTS: Trough exercise duration increased by 115.6 seconds from baseline in both ranolazine groups (pooled) vs 91.7 seconds in the placebo group (P =.01). The times to angina and to electrocardiographic ischemia also increased in the ranolazine groups, at peak more than at trough. The increases did not depend on changes in blood pressure, heart rate, or background antianginal therapy and persisted throughout 12 weeks. Ranolazine reduced angina attacks and nitroglycerin use by about 1 per week vs placebo (P<.02). Survival of 750 patients taking ranolazine during the CARISA trial or its associated long-term open-label study was 98.4% in the first year and 95.9% in the second year. CONCLUSION: Twice-daily doses of ranolazine increased exercise capacity and provided additional antianginal relief to symptomatic patients with severe chronic angina taking standard doses of atenolol, amlodipine, or diltiazem, without evident adverse, long-term survival consequences over 1 to 2 years of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Gibbons, R. J., Abrams, J., Chatterjee, K., Daley, J., Deedwania, P. C., Douglas, J. S., Ferguson, T. B., Fihn, S. D., Fraker, T. D., Gardin, J. M., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02848-6 · Cited by 1,689
Comparison of Coronary-Artery Bypass Surgery and Stenting for the Treatment of Multivessel Disease
Serruys, P. W., Unger, F., Sousa, J. E., Jatene, A., Bonnier, H. J. R. M., Schönberger, J. P. A. M., Buller, N., Bonser, R., van den Brand, M. J. B., van Herwerden, L. A., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441502 · Cited by 1,114
Exercise Treadmill Score for Predicting Prognosis in Coronary Artery Disease
MARK, D. B., HLATKY, M. A., HARRELL, F. E., LEE, K. L., CALIFF, R. M., & PRYOR, D. B. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-6-793 · Cited by 671
Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts
McCormack, J. G., Barr, R. L., Wolff, A. A., & Lopaschuk, G. D. (1996) · Circulation · doi:10.1161/01.cir.93.1.135 · Cited by 291
Self-citationMultiple testing in clinical trials
Bauer, P. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100609 · Cited by 241
Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance
Lawrence Gould, A., & Shih, W. J. (1992) · Communications in Statistics - Theory and Methods · doi:10.1080/03610929208830947 · Cited by 239
Value of exercise treadmill testing in women
Alexander, K. P., Shaw, L. J., DeLong, E. R., Mark, D. B., & Peterson, E. D. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00451-3 · Cited by 233
Hung, J., Lamb, I. H., Connolly, S. J., Jutzy, K. R., Goris, M. L., & Schroeder, J. S. (1983) · Circulation · doi:10.1161/01.cir.68.3.560 · Cited by 158
Fox, K. M., Mulcahy, D., Findlay, I., Ford, I., Dargie, H. J., & on behalf of the TIBET study group (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014699 · Cited by 150
Clarke, B. (1996) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1996.0032 · Cited by 135
Statistical Considerations for Multiplicity in Confirmatory Protocols
Koch, G. G., & Gansky, S. A. (1996) · Drug Information Journal · doi:10.1177/009286159603000228 · Cited by 131
Angina 1 year after percutaneous coronary intervention: A report from the NHLBI Dynamic Registry
Holubkov, R., Laskey, W. K., Haviland, A. M., Slater, J. C., Bourassa, M. G., Vlachos, H. A., Cohen, H. A., Williams, D. O., Kelsey, S. F., & Detre, K. M. (2002) · American Heart Journal · doi:10.1067/mhj.2002.125505 · Cited by 124
Diego, J. M. D., Belardinelli, L., & Antzelevitch, C. N. (2003) · Circulation · doi:10.1161/01.cir.0000085066.05180.40 · Cited by 122
Davies, R. F., Habibi, H., Klinke, W. P., Dessain, P., Nadeau, C., Phaneuf, D. C., Lepage, S., Raman, S., Herbert, M., Foris, K., et al. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)00436-t · Cited by 112
Cocco, G., Rousseau, M. F., Bouvy, T., Cheron, P., Williams, G., Detry, J. M., & Pouleur, H. G. (1992) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199207000-00017 · Cited by 110
PLANNING AND REVISING THE SAMPLE SIZE FOR A TRIAL
Gould, A. L. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140922 · Cited by 109
Metabolic Approaches to the Treatment of Ischemic Heart Disease: The Clinicians' Perspective
Wolff, A. A., Rotmensch, H. H., Stanley, W. C., & Ferrari, R. (2002) · Heart Failure Reviews · doi:10.1023/a:1015384710373 · Cited by 102
Boden, W. E., Bough, E. W., Reichman, M. J., et al. (1985) · Circulation · doi:10.1161/01.cir.71.6.1197 · Cited by 62
Impact of angina burden and other factors on treatment satisfaction after acute coronary syndromes
Beinart, S. C., Sales, A. E., Spertus, J. A., Plomondon, M. E., Every, N. R., & Rumsfeld, J. S. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00256-4 · Cited by 44
Blinded Sample Size Reestimation in Multiarmed Clinical Trials
Kieser, M., & Friede, T. (2000) · Drug Information Journal · doi:10.1177/009286150003400214 · Cited by 34
Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris
PEHRSSON, S. K., Ringqvist, I., Ekdahl, S., Karlson, B. W., Ulvenstam, G., & Persson, S. (2000) · Clinical Cardiology · doi:10.1002/clc.4960231014 · Cited by 32
Cited by
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Myocardial Substrate Metabolism in the Normal and Failing Heart
Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005) · Physiological Reviews · doi:10.1152/physrev.00006.2004 · Cited by 2,048
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Metadata
- Authors
- Chaitman, B. R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-01-21
- Volume
- 291
- Issue
- 3
- Pages
- 309
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2049390983
- Cited by
- 681
- References
- 22
- FWCI
- 30.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.